Cargando…

Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction

BCR/Abl protein drives the onset and progression of Chronic Myeloid Leukemia (CML). We previously showed that BCR/Abl protein is suppressed in low oxygen, where viable cells retain stem cell potential. This study addressed the regulation of BCR/Abl protein expression under oxygen or glucose shortage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bono, Silvia, Lulli, Matteo, D'Agostino, Vito Giuseppe, Gesualdo, Federico Di, Loffredo, Rosa, Cipolleschi, Maria Grazia, Provenzani, Alessandro, Rovida, Elisabetta, Sbarba, Persio Dello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356700/ https://www.ncbi.nlm.nih.gov/pubmed/27852045 http://dx.doi.org/10.18632/oncotarget.13319

Ejemplares similares

Lactate Maintains BCR/Abl Expression and Signaling in Chronic Myeloid Leukemia Cells Under Nutrient Restriction
por: Silvano, Angela, et al.
Publicado: (2022)

Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a “hypoxic” environment
por: Rovida, Elisabetta, et al.
Publicado: (2014)

The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2013)

Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential
por: Poteti, Martina, et al.
Publicado: (2021)

Low-dose methotrexate enhances cycling of highly anaplastic cancer cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage
por: Bono, Silvia, et al.
Publicado: (2018)

The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy
por: Rovida, Elisabetta, et al.
Publicado: (2014)

The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction
por: Cheloni, Giulia, et al.
Publicado: (2017)

Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia
por: Tanturli, Michele, et al.
Publicado: (2011)

AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia
por: Barbetti, V, et al.
Publicado: (2013)

The complex metabolic network gearing the G(1)/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents
por: Stivarou, Theodora, et al.
Publicado: (2015)

The Hedgehog-GLI Pathway Regulates MEK5-ERK5 Expression and Activation in Melanoma Cells
por: Tusa, Ignazia, et al.
Publicado: (2021)

The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines
por: Morandi, Andrea, et al.
Publicado: (2011)

Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy
por: Tubita, Alessandro, et al.
Publicado: (2020)

Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2014)

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
por: Tusa, Ignazia, et al.
Publicado: (2020)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells
por: Tusa, Ignazia, et al.
Publicado: (2018)

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
por: Molica, Matteo, et al.
Publicado: (2020)

Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells
por: Barbetti, Valentina, et al.
Publicado: (2013)

Correction to Barbetti V, et al. Epigenetics Volume 8, Issue 2; pp. 210–9
por: Barbetti, Valentina, et al.
Publicado: (2013)

Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies
por: Liefwalker, Daniel F., et al.
Publicado: (2021)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
por: Tubita, Alessandro, et al.
Publicado: (2022)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Cancer stemness and progression: mitochondria on the stage
por: Chiarugi, Paola, et al.
Publicado: (2015)

NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature
por: Catalano, Gianfranco, et al.
Publicado: (2020)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan
por: Tabassum, Najia, et al.
Publicado: (2014)

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia
por: Cabanas, Hélène, et al.
Publicado: (2018)

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
por: Amin, Huma, et al.
Publicado: (2021)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice
por: Vicente-Dueñas, Carolina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_eu0vh7u691riacgmge97p8h910